Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
(
1 selected
)
Type
Guidance (766)
Guidance programme
(
1 selected
)
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (223)
COVID-19 rapid guidelines (3)
Diagnostics guidance (47)
Health technology evaluations (18)
Highly specialised technologies guidance (28)
Interventional procedures guidance (601)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (339)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (766)
Apply filters
Showing 301 to 350 of 766
Sort by
Date
Title
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Avelumab for untreated metastatic Merkel cell carcinoma
TA691
21 April 2021
21 April 2021
Anakinra for treating Still's disease
TA685
31 March 2021
31 March 2021
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
TA686
31 March 2021
31 March 2021
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
TA687
31 March 2021
31 March 2021
Selective internal radiation therapies for treating hepatocellular carcinoma
TA688
31 March 2021
31 March 2021
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
TA684
17 March 2021
17 March 2021
Erenumab for preventing migraine
TA682
10 March 2021
10 March 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
TA683
10 March 2021
10 March 2021
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
TA680
3 March 2021
3 March 2021
Baricitinib for treating moderate to severe atopic dermatitis
TA681
3 March 2021
3 March 2021
Filgotinib for treating moderate to severe rheumatoid arthritis
TA676
24 February 2021
24 February 2021
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma
TA677
24 February 2021
24 February 2021
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
TA678
24 February 2021
24 February 2021
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
TA679
24 February 2021
24 February 2021
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
TA673
17 February 2021
17 February 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)
TA674
17 February 2021
17 February 2021
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)
TA675
17 February 2021
17 February 2021
Trabectedin for the treatment of advanced soft tissue sarcoma
TA185
24 February 2010
8 February 2021
Mepolizumab for treating severe eosinophilic asthma
TA671
3 February 2021
3 February 2021
Brolucizumab for treating wet age-related macular degeneration
TA672
3 February 2021
3 February 2021
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
TA670
27 January 2021
27 January 2021
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
TA668
6 January 2021
6 January 2021
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
TA666
16 December 2020
16 December 2020
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
TA667
16 December 2020
16 December 2020
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
TA663
9 December 2020
9 December 2020
Liraglutide for managing overweight and obesity
TA664
9 December 2020
9 December 2020
Upadacitinib for treating severe rheumatoid arthritis
TA665
9 December 2020
9 December 2020
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
TA660
25 November 2020
25 November 2020
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
TA661
25 November 2020
25 November 2020
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)
TA662
25 November 2020
25 November 2020
Drug-eluting stents for the treatment of coronary artery disease
TA152
23 July 2008
18 November 2020
Guidance on the use of coronary artery stents
TA71
22 October 2003
18 November 2020
Siponimod for treating secondary progressive multiple sclerosis
TA656
18 November 2020
18 November 2020
Carfilzomib for previously treated multiple myeloma
TA657
18 November 2020
18 November 2020
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
TA658
18 November 2020
18 November 2020
Galcanezumab for preventing migraine
TA659
18 November 2020
18 November 2020
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
TA655
21 October 2020
21 October 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
TA653
14 October 2020
14 October 2020
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
TA654
14 October 2020
14 October 2020
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
TA650
30 September 2020
30 September 2020
Naldemedine for treating opioid-induced constipation
TA651
30 September 2020
30 September 2020
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
TA649
23 September 2020
23 September 2020
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
TA648
9 September 2020
9 September 2020
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)
TA646
2 September 2020
2 September 2020
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
TA647
2 September 2020
2 September 2020
Avelumab with axitinib for untreated advanced renal cell carcinoma
TA645
2 September 2020
2 September 2020
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
TA641
12 August 2020
12 August 2020
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
TA642
12 August 2020
12 August 2020
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
TA643
12 August 2020
12 August 2020
Entrectinib for treating NTRK fusion-positive solid tumours
TA644
12 August 2020
12 August 2020
Previous page
1
…
5
6
Current page
7
8
9
…
16
Page
7
of
16
Next page
Results per page
10
25
50
All
Back to top